A Network Meta-Analysis of Randomized Controlled Trials to Evaluate the Comparative Efficacy of Disease-Modifying Therapies for Patients with Relapsing Multiple Sclerosis
Ofatumumab for Relapsing Multiple Sclerosis: Summary of Global 2022 NMA Update
Interim Results of an Open Label Study to Assess Humoral Immune Response to COVID 19 mRNA Vaccine in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
Safety and Tolerability of Conversion to Siponimod in Patients with Advancing Relapsing Multiple Sclerosis: A Subgroup Analysis by Race and Ethnicity of EXCHANGE Interim Data
Evaluating Humoral Immune Response to mRNA COVID 19 Vaccines in Siponimod treated Patients with Advancing Forms of Relapsing Multiple Sclerosis: A COVID 19 Vaccine Sub study of Phase 3b EXCHANGE Trial
Longitudinal Analysis of Adaptive Immunity Following Additional SARS-CoV-2 Vaccination in MS Patients on Anti-CD20 Therapies and Sphingosine-1-phosphate Receptor Modulators
Early Reduction in Plasma Glial Fibrillary Acidic Protein Levels in Siponimod Treated SPMS Patients (EXPAND) Is Associated With Reduced Risk of Disability Worsening
Effectiveness, Safety, and Patient Reported Outcomes of Ofatumumab in Relapsing Multiple Sclerosis Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design